It is now universally recognized that dysregulation of the regulatory layers above the genome—namely the epigenome consisting of DNA methylation, histone marks and non-coding RNA—is directly involved in producing aberrant gene expression leading to disease. With advances in sequencing technologies, drivers and mechanisms of disease initiation are being unraveled, and a more holistic view of the interplay between the genome and a very active epigenome is taking shape. Importantly, these findings form inextricable causal links between our underlying genome, the regulatory epigenome, and the functional (disease) consequence stemming from both. The Epigenomics in Disease meeting is designed to highlight the interplay between genome-epigenome-disease, while exploring the profound opportunities of applying epigenomic analysis for diagnostics and personalized treatment.
Who should attend: Executives, Directors, Clinicians, Managers, Group Leaders, Researcher Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Epigenetics, Epigenomics, Diagnostics, Research & Development, Cell/Molecular Biology, Oncology and Neurological Disorder Research